Drug intelligence / Profile preview

WPV01 + ritonavir

Development stage: Unknown
Lead developer: Westlake Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

WPV01 + ritonavir is a combination therapy under investigation for the treatment of mild to moderate COVID-19. WPV01 is being evaluated in a Phase III clinical trial for its efficacy and safety in patients with mild or moderate COVID-19 infection. Ritonavir is an oral protease inhibitor primarily used as a pharmacokinetic booster; it inhibits cytochrome P450 3A4, thereby increasing plasma concentrations of co-administered drugs. Ritonavir itself blocks HIV-1 protease, preventing viral replication, but in this context serves to enhance the exposure and effectiveness of WPV01 or other antiviral agents[1][2][3][7]. The developer of WPV01 is Westlake Pharmaceuticals.

Brand names: Norvir

Targets

CYP3A4 (Cytochrome P450 3A4)PR (Progesterone receptor)

Beyond the preview

Go deeper on WPV01 + ritonavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WPV01 + ritonavir.

Explore the full profile